Novartis (NYSE:NVS) Share Price Crosses Below 200 Day Moving Average - Should You Sell?

Novartis logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Novartis shares fell below their 200-day moving average: The stock traded as low as $150.73, below the average of $152.75, and last traded at about $151.34.
  • Growth outlook is mixed: Novartis raised the combined peak-sales outlook for three blockbuster medicines to $18 billion from $14 billion, but lowered its annual sales-growth forecast to 5% from 5%–6%, extending the outlook through 2031.
  • Analyst sentiment is mostly cautious: The stock has an average “Hold” rating and a $152.25 average price target. In its latest reported quarter, Novartis beat consensus estimates for both earnings and revenue.
  • MarketBeat previews the top five stocks to own by December 1st.

Shares of Novartis AG (NYSE:NVS - Get Free Report) crossed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $152.75 and traded as low as $150.73. Novartis shares last traded at $151.3380, with a volume of 3,549,680 shares traded.

Novartis News Summary

Here's some of the latest news about NVS:

  • Positive Sentiment: Novartis raised the combined peak-sales outlook for three blockbuster medicines to $18 billion from $14 billion, a potential growth driver. CNBC article
  • Neutral Sentiment: Management still forecasts 5% annual sales growth through 2031, signaling continued expansion, though at a more measured pace than its former target. Reuters article
  • Negative Sentiment: The company lowered its medium-term sales-growth guidance to 5% annually from a prior 5%–6% forecast, while extending the outlook through 2031. The less ambitious target has pressured sentiment around NVS shares. Reuters article

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. DZ Bank began coverage on shares of Novartis in a report on Wednesday, October 28th. They issued a "hold" rating on the stock. UBS Group restated a "neutral" rating on shares of Novartis in a report on Wednesday, October 28th. JPMorgan Chase & Co. reaffirmed a "buy" rating on shares of Novartis in a research report on Sunday, August 9th. Berenberg Bank reduced their target price on Novartis from $147.00 to $130.00 and set a "hold" rating on the stock in a report on Friday, September 11th. Finally, Weiss Ratings downgraded Novartis from a "buy (b)" rating to a "buy (b-)" rating in a research report on Wednesday, November 4th. Six equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $152.25.

Check Out Our Latest Stock Analysis on NVS

Novartis Stock Performance

The stock's 50 day moving average price is $150.19 and its 200 day moving average price is $152.75. The company has a current ratio of 0.88, a quick ratio of 0.70 and a debt-to-equity ratio of 0.98. The firm has a market cap of $288.78 billion, a PE ratio of 28.88, a P/E/G ratio of 2.84 and a beta of 0.40.

Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.25 by $0.21. The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.53 billion. Novartis had a return on equity of 41.04% and a net margin of 18.11%. The firm's quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.25 EPS. As a group, equities analysts forecast that Novartis AG will post 9.10 earnings per share for the current fiscal year.

Institutional Trading of Novartis

A number of hedge funds have recently made changes to their positions in NVS. Highland Investment Advisors LLC acquired a new position in Novartis during the second quarter worth about $25,000. Evolution Wealth Management Inc. raised its position in Novartis by 552.0% in the second quarter. Evolution Wealth Management Inc. now owns 163 shares of the company's stock worth $26,000 after acquiring an additional 138 shares in the last quarter. Atlatl Advisers LLC bought a new stake in Novartis in the second quarter worth about $26,000. Silicon Valley Capital Partners lifted its holdings in Novartis by 519.4% in the 2nd quarter. Silicon Valley Capital Partners now owns 192 shares of the company's stock valued at $30,000 after acquiring an additional 161 shares during the last quarter. Finally, Curry Webb Wealth Management LLC acquired a new stake in Novartis in the 3rd quarter valued at about $28,000. Hedge funds and other institutional investors own 13.12% of the company's stock.

About Novartis

(Get Free Report)

Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company's medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Novartis Right Now?

Before you consider Novartis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.

While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines